147 related articles for article (PubMed ID: 33758143)
41. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
42. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
43. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
[TBL] [Abstract][Full Text] [Related]
44. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
45. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
46. Ki67 index and mitotic count: Correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors.
Huang W; Nebiolo C; Esbona K; Hu R; Lloyd R
Ann Diagn Pathol; 2020 Oct; 48():151586. PubMed ID: 32836178
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Monitor-Image and Printout-Image Methods in Ki-67 Scoring of Gastroenteropancreatic Neuroendocrine Tumors.
Dogukan FM; Yilmaz Ozguven B; Dogukan R; Kabukcuoglu F
Endocr Pathol; 2019 Mar; 30(1):17-23. PubMed ID: 30367334
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
49. Automated quantification of Ki67/MART1 stains may prevent false-negative melanoma diagnoses.
Wandler A; Spaun E; Steiniche T; Nielsen PS
J Cutan Pathol; 2016 Nov; 43(11):956-962. PubMed ID: 27461337
[TBL] [Abstract][Full Text] [Related]
50. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
51. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
52. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?
Grillo F; Valle L; Ferone D; Albertelli M; Brisigotti MP; Cittadini G; Vanoli A; Fiocca R; Mastracci L
Endocrine; 2017 Sep; 57(3):494-502. PubMed ID: 28726181
[TBL] [Abstract][Full Text] [Related]
53. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
54. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
[TBL] [Abstract][Full Text] [Related]
55. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
56. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
57. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
58. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
Singh S; Hallet J; Rowsell C; Law CH
Eur J Surg Oncol; 2014 Nov; 40(11):1517-22. PubMed ID: 25088936
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
